Questions across 4 calls

Bansi Desai

JPMorgan

Global Health Limited

Global Health Limited CC-May26.pdf · 2026-05-15

Congrats on a good set of numbers. So my first question is on Noida. Now that we are inching closer towards break-even in this fiscal. Historically, you've seen very strong ramp -up for our newer units, be it Lucknow, Patna. I know, Pankaj, you've always cautioned us that don't simply extrapolate. But should we think about Noida's ramp-up differently more so because this is also a region of our core strength where we have a very strong ecosystem. So should we think any differently post the break-even?

Also, Pankaj, were these more underserved markets in general? I mean, Noida doesn't appear to be underserved at least on face of it, but you are highlighting that at least structurally demand doesn't seem to be a problem. So should we think of that as a factor as well?

Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited CC-Feb26.pdf · 2026-01-29

Just a follow-up on occupancy. I'm sorry to harp on it. If the seasonality continues to remain subdued going into the next year, do we see ourselves going past 50% occupancy levels just driven by the measures that we are undertaking?

Thanks for that, sir. And besides these marketing-led efforts, if you could illustrate the efforts that you are undertaking? I mean, are these in lines of adding more doctors or, again, doing more complex work? If you could illustrate what are these efforts?

Alkem Laboratories Limited

Alkem Laboratories Limited CC-Nov25.pdf · 2025-11-13

Sir, my first question is on penicillin G. We hear that the government is reportedly considering imposing MIP minimum import price on penicilli n G. We would love to hear your thoughts. Any impact that it could have on us? Could this reverse any benefits that we would have seen?

Appreciate, sir. And second is ex of R&D, if we look at the other e xpenses, they have sharply increased sequentially by almost INR200 crores. So what has driven that?

Fortis Healthcare Limited

Fortis Healthcare Limited CC-Dec23.pdf · 2024-02-08

My question is on some of our low -margin hospitals. We have almost 150 beds, which one - fourth of our capacity which are right now yielding less than 10% margin. I know the hospitals here. Each of them have a unique set of challenges. But how is the management thinking about the turnaround here? And should we expect this cohort to have a gradual improvement or this should also contribute meaningfully to our margin improvement goal going forward?

And my second question is on the general pricing levels in the industry today. We've seen very strong ARPOP in the industry over the last four, five years. Is insurance regulator worried about these pricing levels? Are you having any kind of dialogue with them? Are they seeing these prices to be high? Or do you think these price increases are largely taken to meet the medical cost inflation and therefore, are justified from that perspective. So any colour on the pricing dialog that you could be having with the insurance regulator on how they are viewing the pricing today in the industry?